Barriers to drug delivery in solid tumors
暂无分享,去创建一个
Vladimir P Torchilin | V. Torchilin | Shravan Kumar Sriraman | Bhawani Aryasomayajula | Bhawani Aryasomayajula | S. Sriraman
[1] Jan E Schnitzer,et al. Overcoming in vivo barriers to targeted nanodelivery. , 2011, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[2] Ezequiel Bernabeu,et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. , 2012, Biochimica et biophysica acta.
[3] Q. Lu,et al. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer. , 2013, Biomaterials.
[4] V. Torchilin,et al. Phospholipid–polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery , 2011, Drug Delivery and Translational Research.
[5] R. Giavazzi,et al. Matrix metalloproteinase inhibition: a review of anti-tumour activity. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Olga Kovalchuk,et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin , 2008, Molecular Cancer Therapeutics.
[7] K. Brew,et al. Reactive Site Mutations in Tissue Inhibitor of Metalloproteinase-3 Disrupt Inhibition of Matrix Metalloproteinases but Not Tumor Necrosis Factor-α-converting Enzyme* , 2005, Journal of Biological Chemistry.
[8] G. Wood,et al. Targeted nanoparticulate drug-delivery systems for treatment of solid tumors: a review. , 2010, Therapeutic delivery.
[9] S. Hanada,et al. Expression of the multidrug transporter, P‐glycoprotein, in acute leukemia cells and correlation to clinical drug resistance , 1990, Cancer.
[10] W. Kuebler,et al. Co‐regulation of Transcellular and Paracellular Leak Across Microvascular Endothelium By Dynamin and Rac , 2012, The American journal of pathology.
[11] Marianne Fillet,et al. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells , 2003, Oncogene.
[12] P. Sutphin,et al. Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy , 2007, Proceedings of the National Academy of Sciences.
[13] C. Hopkins,et al. Signal-dependent membrane protein trafficking in the endocytic pathway. , 1993, Annual review of cell biology.
[14] D. Talbot,et al. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. , 1996, European journal of cancer.
[15] P. Low,et al. Ligand Binding and Kinetics of Folate Receptor Recycling in Vivo: Impact on Receptor-Mediated Drug Delivery , 2004, Molecular Pharmacology.
[16] M Ferrari,et al. Size and shape effects in the biodistribution of intravascularly injected particles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[17] Cui Tang,et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. , 2010, Biomaterials.
[18] M. Papisov,et al. Why do Polyethylene Glycol-Coated Liposomes Circulate So Long?: Molecular Mechanism of Liposome Steric Protection with Polyethylene Glycol: Role of Polymer Chain Flexibility , 1994 .
[19] R M Heethaar,et al. Blood platelets are concentrated near the wall and red blood cells, in the center in flowing blood. , 1988, Arteriosclerosis.
[20] Pallavi Sethi,et al. Tumor microenvironment and nanotherapeutics. , 2013, Translational cancer research.
[21] J. Cooper,et al. Endothelial barrier function. , 1989, The Journal of investigative dermatology.
[22] Masahiro Hiraoka,et al. Optical Imaging of Tumor Hypoxia and Evaluation of Efficacy of a Hypoxia-Targeting Drug in Living Animals , 2005, Molecular imaging.
[23] R. Gillies,et al. pH and drug resistance in tumors. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[24] Giulio Caracciolo,et al. Effect of DOPE and cholesterol on the protein adsorption onto lipid nanoparticles , 2013, Journal of Nanoparticle Research.
[25] Hideyoshi Harashima,et al. Enhanced Hepatic Uptake of Liposomes Through Complement Activation Depending on the Size of Liposomes , 1994, Pharmaceutical Research.
[26] Xìao-chun Xu,et al. Prognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancer , 2008, International journal of cancer.
[27] Lin Zhang,et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells , 2011, Nature.
[28] Vladimir P Torchilin,et al. Enhanced transfection of tumor cells in vivo using “Smart” pH-sensitive TAT-modified pegylated liposomes , 2007, Journal of drug targeting.
[29] D. Hanahan,et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.
[30] W. Stetler-Stevenson,et al. Proteases in invasion: matrix metalloproteinases. , 2001, Seminars in cancer biology.
[31] Wen-Qi Jiang,et al. Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar , 2013, PloS one.
[32] Dai Fukumura,et al. Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize , 2007, Journal of cellular biochemistry.
[33] Y. Maitani,et al. Cationic liposome (DC-Chol/DOPE=1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression. , 2007, International journal of pharmaceutics.
[34] Ning Gu,et al. Preparation, characterization and evaluation of breviscapine lipid emulsions coated with monooleate-PEG-COOH. , 2011, International journal of pharmaceutics.
[35] Vladimir P Torchilin,et al. Multifunctional nanocarriers. , 2006, Advanced drug delivery reviews.
[36] Nicholas Denko,et al. Overcoming Physiologic Barriers to Cancer Treatment by Molecularly Targeting the Tumor Microenvironment , 2006, Molecular Cancer Research.
[37] Vladimir P Torchilin,et al. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. , 2013, Biomaterials.
[38] J. Garcia,et al. Lung endothelial heparan sulfates mediate cationic peptide-induced barrier dysfunction: a new role for the glycocalyx. , 2003, American journal of physiology. Lung cellular and molecular physiology.
[39] J. Benoit,et al. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. , 2006, Journal of biomedical materials research. Part A.
[40] Francesco Stellacci,et al. Effect of surface properties on nanoparticle-cell interactions. , 2010, Small.
[41] Philip S Low,et al. Folate-mediated delivery of macromolecular anticancer therapeutic agents. , 2002, Advanced drug delivery reviews.
[42] Rakesh K. Jain,et al. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.
[43] Umesh Kumar,et al. Cellular Binding of Anionic Nanoparticles is Inhibited by Serum Proteins Independent of Nanoparticle Composition. , 2013, Biomaterials science.
[44] S. Zahler,et al. Endothelial Glycocalyx as an Additional Barrier Determining Extravasation of 6% Hydroxyethyl Starch or 5% Albumin Solutions in the Coronary Vascular Bed , 2004, Anesthesiology.
[45] Vladimir P Torchilin,et al. Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes , 2012, Cancer biology & therapy.
[46] Chi-Hwa Wang,et al. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. , 2013, Biomaterials.
[47] R. Jain,et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.
[48] L. Matrisian,et al. Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.
[49] Brenda Baggett,et al. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. , 2003, Biochemical pharmacology.
[50] Krishnamurthy V. Nemani,et al. The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition. , 2012, Developmental cell.
[51] E. Rofstad,et al. High Interstitial Fluid Pressure Is Associated with Tumor-Line Specific Vascular Abnormalities in Human Melanoma Xenografts , 2012, PloS one.
[52] Gaurav Sahay,et al. Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[53] Y. Boucher,et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Katharina Landfester,et al. Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. , 2011, ACS nano.
[55] R. Brock,et al. Cell surface clustering of heparan sulfate proteoglycans by amphipathic cell-penetrating peptides does not contribute to uptake. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[56] I. Zuhorn,et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. , 2004, The Biochemical journal.
[57] D. Pinsky,et al. Targeting therapeutics to the vascular wall in atherosclerosis--carrier size matters. , 2011, Atherosclerosis.
[58] L. Liotta,et al. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. , 1974, Cancer research.
[59] Carlos López-Otín,et al. Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.
[60] Palmitoyl Ascorbate Liposomes and Free Ascorbic Acid: Comparison of Anticancer Therapeutic Effects Upon Parenteral Administration , 2012, Pharmaceutical Research.
[61] Phapanin Charoenphol,et al. Potential role of size and hemodynamics in the efficacy of vascular-targeted spherical drug carriers. , 2010, Biomaterials.
[62] R. van Furth. The mononuclear phagocyte system. , 1980, Verhandlungen der Deutschen Gesellschaft fur Pathologie.
[63] I. Elkin,et al. Drug-loaded nanocarriers: passive targeting and crossing of biological barriers. , 2012, Current medicinal chemistry.
[64] Dieter Haemmerich,et al. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[65] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[66] Angelo Corti,et al. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. , 2002, The Journal of clinical investigation.
[67] Vladimir P Torchilin,et al. Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice. , 2008, International journal of pharmaceutics.
[68] A. Hilgeroth,et al. Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties. , 2013, Bioorganic & medicinal chemistry.
[69] Long Yu,et al. Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells. , 2012, European journal of pharmacology.
[70] P. Charoenphol,et al. Particle-cell dynamics in human blood flow: implications for vascular-targeted drug delivery. , 2012, Journal of biomechanics.
[71] H. Kim,et al. An efficient liposomal gene delivery vehicle using Sendai F/HN proteins and protamine , 2008, Cancer Gene Therapy.
[72] Lin Zhu,et al. Stimulus-responsive nanopreparations for tumor targeting. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[73] Parag Aggarwal,et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.
[74] Daniel G. Anderson,et al. Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.
[75] D. Tzemach,et al. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[76] A. Davidoff,et al. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. , 2002, Blood.
[77] M Beth McCarville,et al. Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy , 2007, Clinical Cancer Research.
[78] Vladimir P Torchilin,et al. Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[79] S. Parveen,et al. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. , 2011, European journal of pharmacology.
[80] K. Chen,et al. Nanoparticles meet cell membranes: probing nonspecific interactions using model membranes. , 2014, Environmental science & technology.
[81] A. Dufour,et al. Inhibition of Matrix Metalloproteinase 14 (MMP-14)-mediated Cancer Cell Migration* , 2011, The Journal of Biological Chemistry.
[82] L. Gerweck,et al. The pH partition theory predicts the accumulation and toxicity of doxorubicin in normal and low-pH-adapted cells , 1999, British Journal of Cancer.
[83] S. Leung,et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. , 2011, Cancer research.
[84] V. Torchilin,et al. Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery. , 2012, Biomaterials.
[85] C. Overall,et al. Towards third generation matrix metalloproteinase inhibitors for cancer therapy , 2006, British Journal of Cancer.
[86] Christina L. Ting,et al. Interactions of a charged nanoparticle with a lipid membrane: implications for gene delivery. , 2011, Biophysical journal.
[87] Vladimir P Torchilin,et al. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[88] D. Hallahan,et al. Proteolytic surface functionalization enhances in vitro magnetic nanoparticle mobility through extracellular matrix. , 2006, Nano letters.
[89] Stephen Gould,et al. Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells , 2011, Proceedings of the National Academy of Sciences.
[90] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[91] B. Zhang,et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. , 2013, Biomaterials.
[92] A. Degterev,et al. Micellar formulations of pro-apoptotic DM-PIT-1 analogs and TRAIL in vitro and in vivo , 2013, Drug delivery.
[93] R. Athawale,et al. Studies on stabilization mechanism and stealth effect of poloxamer 188 onto PLGA nanoparticles. , 2013, Colloids and surfaces. B, Biointerfaces.
[94] Jun Qian,et al. Up-regulating Blood Brain Barrier Permeability of Nanoparticles via Multivalent Effect , 2013, Pharmaceutical Research.
[95] V. Torchilin,et al. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. , 2013, Biomaterials.
[96] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[97] M. Junttila,et al. Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.
[98] Sara Linse,et al. Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.
[99] A. Corti,et al. Tumor Vascular Targeting with Tumor Necrosis Factor α and Chemotherapeutic Drugs , 2004 .
[100] M. Dewhirst,et al. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation , 2006, British Journal of Cancer.
[101] P. Kristjansen,et al. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. , 2007, Neoplasia.
[102] V. Torchilin,et al. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models , 2014, Cancer biology & therapy.
[103] J. Panyam,et al. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[104] P. Jones,et al. Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells. , 1980, Cancer research.
[105] J. Kamps,et al. The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. , 2005, Biochemical and biophysical research communications.
[106] Lin Zhu,et al. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. , 2012, ACS nano.
[107] G. Fleuren,et al. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer , 2001, Histochemistry and Cell Biology.
[108] Gert Storm,et al. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system , 1995 .
[109] A. Corti,et al. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. , 2004, Annals of the New York Academy of Sciences.
[110] V. Yang,et al. Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours , 2008, BMC Cancer.
[111] A. Zhang,et al. Study of non-uniform nanoparticle liposome extravasation in tumour , 2005, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[112] W. Mark Saltzman,et al. Dilation and degradation of the brain extracellular matrix enhances penetration of infused polymer nanoparticles , 2007, Brain Research.
[113] V. Torchilin,et al. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. , 2012, Nanomedicine.
[114] Vladimir P Torchilin,et al. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. , 2011, International journal of pharmaceutics.
[115] Jian Ding,et al. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-α carriers , 2001 .
[116] L. Liotta,et al. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[117] I. Zuhorn,et al. Gene delivery by cationic lipid vectors: overcoming cellular barriers , 2007, European Biophysics Journal.
[118] Kit S Lam,et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. , 2011, Biomaterials.
[119] A. Bikfalvi,et al. Tumor angiogenesis , 2020, Advances in cancer research.
[120] E. Rofstad,et al. Quantitative assessment of uptake and distribution of iron oxide particles (NC100150) in human melanoma xenografts by contrast‐enhanced MRI , 2004, Magnetic resonance in medicine.
[121] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[122] Vladimir P Torchilin,et al. The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy , 2013, Journal of drug targeting.
[123] A Ciechanover,et al. Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. , 1983, The Journal of biological chemistry.
[124] V. Torchilin,et al. Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. , 2013, Cancer letters.
[125] Yan Zhang,et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[126] Chen Jiang,et al. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. , 2013, International journal of pharmaceutics.
[127] Si-Shen Feng,et al. Effects of Particle Size and Surface Modification on Cellular Uptake and Biodistribution of Polymeric Nanoparticles for Drug Delivery , 2013, Pharmaceutical Research.
[128] V. Torchilin,et al. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety , 2013, Proceedings of the National Academy of Sciences.
[129] I. Tannock,et al. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. , 1997, British Journal of Cancer.
[130] M. Hiraoka,et al. Tumor hypoxia: A target for selective cancer therapy , 2003, Cancer science.
[131] Vladimir P. Torchilin,et al. Liposomes as ‘smart’ pharmaceutical nanocarriers , 2010 .
[132] Ajit Varki,et al. Molecular basis of metastasis. , 2009, The New England journal of medicine.
[133] Charles R. Martin. Nanomedicine: a great first year and, with your help, a bright future ahead , 2007 .
[134] Jianjun Cheng,et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles , 2004, Cancer biology & therapy.
[135] Jiuhong Kang,et al. Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression* , 2013, The Journal of Biological Chemistry.
[136] Vladimir P Torchilin,et al. Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. , 2013, Cancer letters.
[137] J. S. Rao,et al. Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. , 2008, Cancer research.
[138] Quanyin Hu,et al. Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy. , 2014, Molecular pharmaceutics.
[139] Jianqing Gao,et al. Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome. , 2013, International journal of pharmaceutics.
[140] R. Jain,et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.
[141] W. Stetler-Stevenson,et al. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. , 1999, The Journal of clinical investigation.
[142] Bert Vogelstein,et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[143] Tao Zhang,et al. Pigment epithelium-derived factor inhibits glioma cell growth in vitro and in vivo. , 2007, Life sciences.
[144] R K Jain,et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. , 1999, Cancer research.
[145] Ulo Langel,et al. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. , 2005, Advanced drug delivery reviews.
[146] Yu-Lan Hu,et al. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. , 2013, Biomaterials.
[147] S. Biswas,et al. Hypoxia-targeted siRNA delivery. , 2014, Angewandte Chemie.
[148] A. Corti,et al. Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-α , 2006, Clinical Cancer Research.
[149] Vladimir P Torchilin,et al. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. , 2009, International journal of pharmaceutics.
[150] Alex Vitkin,et al. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. , 2006, Cancer research.
[151] S. Pun,et al. Increased nanoparticle penetration in collagenase-treated multicellular spheroids , 2007, International journal of nanomedicine.